ABSTRACT
SARS-CoV-2 antibody levels associated with reduced hospitalization risk remain undefined. Our outpatient COVID-19 convalescent plasma (CCP), placebo-controlled trial observed SARS-CoV-2 antibody levels decreasing 22-fold from matched donor units into post-transfusion seronegative recipients. Unvaccinated recipients were jointly stratified by a) early or late transfusion (≤ 5 or >5 days from symptom onset) and b) high or low post-transfusion SARS-CoV-2 antibody levels (< or ≥ geometric mean). Early treatment with high post-transfusion antibody levels reduced hospitalization risk-0/102 (0%) compared to all other CCP recipients-17/370 (4.6%; Fisher exact p=0.03) and to all control plasma recipients-35/461 (7.6%; Fisher exact p=0.001). A similar donor upper/lower antibody level and early late transfusion stratified analyses indicated significant hospital risk reduction. Pre-transfusion nasal viral loads were similar in CCP and control recipients regardless of hospitalization outcome. Therapeutic CCP should comprise the upper 30% of donor antibody levels to provide effective outpatient use for immunocompromised and immunocompetent outpatients.
Competing Interest Statement
TG- Paid consultant and employee of Fenwal, a Fresenius Kabi company; AC- Scientific Advisory Board of Sabtherapeutics (cow-derived human immunoglobulins COVID-19 treatment and other infectious diseases) and Ortho Diagnostics Speakers Bureau; EB- member of the FDA Blood Products Advisory Committee, Abbot Laboratories, Grifols Diagnostic Solutions and Terumo BCT: personal fee for invited educational presentations; California Institute for Regenerative Medicine: Advisor. SS reports research grants; F2G, Cidara, Ansun, Zeteo, Emergent Biosolutions: personal fees as consultant, advisory board, data safety monitoring board member; Celltrion, Adagio, Immunome, Adamis, Karyopharm, Intermountain Health: Stock options: Immunome; CS: Centers for Disease Control and Prevention, Merck, Pfizer: Research Grants. All other authors report no relevant disclosures.
Clinical Trial
NCT04373460
Funding Statement
Supported by a contract (W911QY2090012, to Dr. Sullivan) with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense of the Department of Defense, in collaboration with the Defense Health Agency; Bloomberg Philanthropies; the State of Maryland; a grant (3R01AI152078-01S1, to Dr. Casadevall) from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID); a grant (U24TR001609-S3, to Dr. Hanley) from the NIH National Center for Advancing Translational Sciences; a grant (1K23HL151826NIH, to Dr. Bloch) from the National Heart, Lung, and Blood Institute; the Division of Intramural Research, NIAID, NIH; the Mental Wellness Foundation; the Moriah Fund; Octapharma; the Healthnetwork Foundation; and the Shear Family Foundation. The study sponsors did not contribute to the study design, the collection, analysis, and interpretation of data, and the decision to submit the paper for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review board of Johns Hopkins University served as the single institutional review board. For the Center for American Indian Health sites, the protocol was independently reviewed and approved by the Navajo Nation Human Research Review Board and the Indian Health Service National Institutional Review Board. The protocol was also approved by the Human Research Protection Office of the Department of Defense. An independent medical monitor who was unaware of the trial group assignments reviewed all serious adverse events, and an independent panel of three physicians who were unaware of the trial-group assignments adjudicated Covid 19 related hospitalizations and severity. An independent data and safety monitoring board provided interim safety and efficacy reviews. The trial was conducted in accordance with the principles of the Declaration of Helsinki, the Good Clinical Practice guidelines of the International Council for Harmonisation, and all applicable regulatory requirements.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵# These authors jointly supervised this work: Sabra Klein, David Sullivan
In the Medrxiv author list Sitaras was spelled Sitaris. The pdf version was correct. There was a typo in the authjor list that showed up in the initial page. This was updated and also minor edits for the final submitted pdf to journal were made for figure clarifications
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- CCP
- COVID-19 convalescent plasma
- RCT
- randomized controlled trial
